CATEGORIE

New PLENVU® (NER1006) Data at ACG Showing Superior Bowel Cleansing to Commonly Used Preparations

domenica 22 ottobre 2017

2' di lettura

- Norgine B.V. today presented new data demonstrating the superior high-quality bowel cleansing efficacy (in at least one segment of the colon) of PLENVU® (NER1006) compared to two widely used alternative bowel preparations: sodium picosulfate and magnesium salt solution (CITRAFLEET®) and 2-litre PEG with ascorbate (MOVIPREP®). The data were presented at the World Congress of Gastroenterology at the American College of Gastroenterology (ACG) in Orlando, Florida, USA. PLENVU® is a novel 1-litre polyethylene glycol (PEG)-based bowel preparation currently under regulatory review in the US and EU.      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) The post-hoc analysis of three phase III clinical trials - DAYB, MORA and NOCT - evaluated high-quality cleansing results (one segment with Boston Bowel Preparation Scale score 3 and all other segments scores >2). The results showed that PLENVU® produced significantly higher rates of high quality cleansing: PLENVU® achieved similar high-quality cleansing results as a trisulfate solution in the NOCT study (32.6% vs. 35.1%, p=0.63). Assessment of adequate cleansing (BBPS segmental score >2) in the overall colon and the right colon showed that PLENVU® produced numerically higher results compared to all three alternative preparations. A separate post-hoc analysis of the DAYB, MORA and NOCT trials found a positive relationship between cleansing grade and improved lesion detection rates, suggesting that high-quality bowel cleansing may improve polyp and adenoma detection rates in the overall colon. Dr Cesare Hassan of the Nuovo Regina Margherita Hospital, Rome, Italy said, "These results confirm that PLENVU® achieves consistent excellent bowel cleansing, with lower volume intake, compared to widely used alternative preparations. Combined with the finding that better cleansing may improve polyp and adenoma detection, PLENVU® has the potential to improve outcomes and save healthcare resources." He added, "The very high quality of the PLENVU® studies emphasise that these results are robust and irreversible." Media Contacts:  Isabelle Jouin, T: +44(0)1895-453643Charlotte Andrews, T: +44(0)1895-453607 Follow us @norgine  

tag

Ti potrebbero interessare

TRANSIZIONE 5.0: CASASCO, NECESSARIE SOLUZIONI PER LA PIENA FRUIBILITÀ DEI CREDITI DI IMPOSTA

“Il DL 38/2026 (modificato dal DL 42, entrambi in corso di esame al Senato), risolvono quasi integralmente, la que...

Versilfood avvia l’ampliamento del polo produttivo di Camaiore

Nuove linee automatizzate, maggiore capacità produttiva e un ulteriore passo avanti nel percorso di crescita fond...

Foglio Edizioni Libri: al via il nuovo progetto editoriale di Valter Mainetti 

L’11 settembre resta una data scolpita nella storia contemporanea, uno spartiacque che ha segnato il primo attacco...

Vecchioni e Dompé, Opa sulle azioni di B.F: la società resta quotata

Arum (società del presidente esecutivo di B.F Federico Vecchioni) e Dompé Holdings (che fa riferimento a S...